Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2596-2602

  Hafner, Verena ^a   Czock, David ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Bommer, Jürgen ^b   Mikus, Gerd ^a   Machleidt, Christoph ^c   Weinreich, Thomas ^d   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Heimdialyse   (Germany)

^c Nephrologisches Zentrum   (Germany)

^d Duale Hochschule Villingen Schwenningen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; DRUG METABOLITE; POLYSULFONE; UK 115794; UNCLASSIFIED DRUG; VORICONAZOLE; VORICONAZOLE N OXIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSATE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SOLUBILIZATION; STEADY STATE; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIFUNGAL AGENTS; BETA-CYCLODEXTRINS; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRIMIDINES; RENAL DIALYSIS; SOLVENTS; TRIAZOLES;

EID: 77952594210     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01540-09     Document Type: Article

References (19)

1. Abel, S., R. Allan, K. Gandelman, K. Tomaszewski, D. J. Webb, and N. D. Wood. 2008. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin. Drug Investig. 28:409-420.
2. Bayliss, M. A. J., R. Gage, A. M. Edgington, and R. F. Venn. 2000. Fluorescence determination of sulphobutylether-beta-cyclodextrin sodium in human plasma and urine by size-exclusion chromatography with inclusion complex formation. Chromatographia 52:S83-S86.
3. Fliser, D., and J. T. Kielstein. 2006. Treatment of renal failure in the intensive care unit with extended dialysis. Nat. Clin. Pract. Nephrol. 2:32-39.
4. Gage, R., R. F. Venn, M. A. Bayliss, A. M. Edgington, S. J. Roffey, and B. Sorrell. 2000. Fluorescence determination of sulphobutylether-beta- cyclodextrin in human plasma by size exclusion chromatography with inclusion complex formation. J. Pharm. Biomed. Anal. 22:773-780.
5. Ghannoum, M. A., and D. M. Kuhn. 2002. Voriconazole-better chances for patients with invasive mycoses. Eur. J. Med. Res. 7:242-256.
6. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
7. Kamel Mohamed, O. H., I. M. Wahba, S. Watnick, S. B. Earle, W. M. Bennett, J. W. Ayres, and M. Y. Munar. 2007. Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen. Clin. J. Am. Soc. Nephrol. 2:694-699.
8. Karlsson, M. O., I. Lutsar, and P. A. Milligan. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53:935-944.
9. Kullberg, B. J., J. D. Sobel, M. Ruhnke, P. G. Pappas, C. Viscoli, J. H. Rex, J. D. Cleary, E. Rubinstein, L. W. P. Church, J. M. Brown, H. T. Schlamm, I. T. Oborska, F. Hilton, and M. R. Hodges. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366: 1435-1442.
10. Loftsson, T., and M. E. Brewster. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85:1017-1025.
11. Mansour, D., P. Inki, and K. Gemzell-Danielsson. 2010. Efficacy of contraceptive methods: a review of the literature. Eur. J. Contracept. Reprod. Health Care 15:4-16.
12. Muhl, E. 2005. Antimycotic drugs under continuous renal replacement therapy. Mycoses 48:56-60.
13. Saran, R., J. L. Bragg-Gresham, N. W. Levin, Z. J. Twardowski, V. Wizemann, A. Saito, N. Kimata, B. W. Gillespie, C. Combe, J. Bommer, T. Akiba, D. L. Mapes, E. W. Young, and F. K. Port. 2006. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 69:1222-1228.
14. Sowinski, K. M., S. J. Magner, A. Lucksiri, M. K. Scott, R. J. Hamburger, and B. A. Mueller. 2008. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin. J. Am. Soc. Nephrol. 3:355-361.
15. Stella, V. J., and R. A. Rajewski. 1997. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14:556-567.
16. Takezawa, K., I. Okamoto, M. Fukuoka, and K. Nakagawa. 2008. Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. J. Thorac. Oncol. 3:1073-1075.
17. U.S. Food and Drug Administration Antiviral Drugs Advisory Committee. 2001. 4-October-2001 Briefing document for voriconazole (oral and intravenous formulations). U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/ohrms/dockets/AC/01/briefing/3792b2-01-Pfizer.pdf.
18. U.S. Food and Drug Administration Biopharmaceutics Coordinating Committee. 2001. Guidance for industry: bioanalytical method validation. Biopharmaceutics Coordinating Committee, Center for Drug Evaluation and Research (CDER) in cooperation with Center for Veterinary Medicine (CVM) at the U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
19. von Mach, M. A., J. Burhenne, and L. S. Weilemann. 2006. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin. Pharmacol. 6:6.